Shares of Sierra Oncology Inc (NASDAQ:SRRA) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Brokers have set a 12 month consensus price objective of $32.00 for the company and are forecasting that the company will post ($2.20) EPS for the current quarter, according to Zacks. Zacks has also assigned Sierra Oncology an industry rank of 50 out of 254 based on the ratings given to its competitors.
SRRA has been the subject of several research analyst reports. Oppenheimer reissued a “buy” rating on shares of Sierra Oncology in a research note on Wednesday, May 13th. Zacks Investment Research cut Sierra Oncology from a “buy” rating to a “hold” rating in a report on Thursday.
Shares of NASDAQ:SRRA traded down $0.78 during midday trading on Monday, hitting $12.96. The stock had a trading volume of 103 shares, compared to its average volume of 35,672. The business’s 50-day simple moving average is $12.74 and its 200-day simple moving average is $8.43. Sierra Oncology has a 12 month low of $8.55 and a 12 month high of $29.04. The company has a market cap of $145.85 million, a P/E ratio of -0.53 and a beta of 1.33.
Sierra Oncology (NASDAQ:SRRA) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($1.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.74) by $1.43. On average, research analysts predict that Sierra Oncology will post -9.57 EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in SRRA. Virtu Financial LLC bought a new stake in shares of Sierra Oncology in the 4th quarter worth approximately $59,000. Acadian Asset Management LLC raised its stake in Sierra Oncology by 52.5% during the fourth quarter. Acadian Asset Management LLC now owns 1,371,616 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 472,395 shares during the last quarter. Renaissance Technologies LLC raised its stake in Sierra Oncology by 31.3% during the fourth quarter. Renaissance Technologies LLC now owns 3,456,465 shares of the biotechnology company’s stock valued at $1,183,000 after buying an additional 824,701 shares during the last quarter. VR Adviser LLC purchased a new position in shares of Sierra Oncology in the first quarter worth $4,822,000. Finally, Abingworth LLP raised its stake in shares of Sierra Oncology by 304.6% in the first quarter. Abingworth LLP now owns 876,541 shares of the biotechnology company’s stock worth $8,590,000 after purchasing an additional 659,874 shares during the last quarter. 67.30% of the stock is currently owned by institutional investors.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
See Also: Bollinger Bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.